Valuation: Photocure ASA

Market Cap 149.26Cr 16Cr 14Cr 13Cr 12Cr 22Cr 1.5TCr 22Cr 151.11Cr 59Cr 737.6Cr 58Cr 57Cr 2.55TCr P/E 2026 *
16.5x
P/E 2027 * 34.8x
Enterprise Value 129Cr 13Cr 12Cr 11Cr 10Cr 19Cr 1.3TCr 19Cr 130.59Cr 51Cr 637.45Cr 51Cr 49Cr 2.2TCr EV / Sales 2026 *
1.96x
EV / Sales 2027 * 1.91x
Free-Float
94.52%
Yield 2026 *
-
Yield 2027 * -
1 day-0.53%
1 week-2.77%
Current month-5.40%
1 month-6.19%
3 months-17.50%
6 months-22.51%
Current year-21.43%
1 week 54.8
Extreme 54.8
58.3
1 month 54.8
Extreme 54.8
61.8
Current year 54.8
Extreme 54.8
79.8
1 year 50.5
Extreme 50.5
79.8
3 years 40.7
Extreme 40.7
79.8
5 years 40.7
Extreme 40.7
145
10 years 21.5
Extreme 21.5
154.5
Manager TitleAgeSince
Chief Executive Officer - 01/11/2018
Chief Tech/Sci/R&D Officer - 01/08/2021
Human Resources Officer - 01/02/2021
Director TitleAgeSince
Director/Board Member - 01/01/2022
Chairman - 27/09/2023
Director/Board Member - 23/05/2024
Date Insider Type Main position Quantity % Market Cap.
02/04/25 BuyCompany 11,355 0.0419%
02/04/25 BuyCompany 8,997 0.0332%
31/03/25 BuyCompany 21,105 0.0778%
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-2.77%-8.03%+18.48% 16Cr
+0.86%+1.43%+47.17%+161.40% 1,06700Cr
+1.59%+4.09%+56.51%+52.79% 63TCr
+0.95%+1.91%+36.30%+83.13% 46TCr
+1.60%+6.25%+37.00%+30.00% 35TCr
-0.60%+1.52%+36.67%+39.80% 30TCr
-0.14%+0.60%+17.29%+18.19% 26TCr
+0.09%-2.82%-29.09%-41.29% 22TCr
+1.22%+2.66%+22.66%+59.81% 20TCr
-1.18%-3.70%+11.28%+67.43% 16TCr
Average +0.39%+0.92%+22.78%+48.97% 36.44TCr
Weighted average by Cap. +0.76%+1.95%+35.99%+78.14%

Financials

2026 *2027 *
Net sales 66Cr 6.89Cr 6.05Cr 5.62Cr 5.16Cr 9.7Cr 663.05Cr 9.85Cr 67Cr 26Cr 325.98Cr 26Cr 25Cr 1.13TCr 66Cr 6.94Cr 6.09Cr 5.67Cr 5.2Cr 9.77Cr 668.08Cr 9.92Cr 67Cr 26Cr 328.45Cr 26Cr 25Cr 1.14TCr
Net income 9.13Cr 95.33L 83.73L 77.86L 71.45L 1.34Cr 92Cr 1.36Cr 9.25Cr 3.61Cr 45Cr 3.58Cr 3.5Cr 156.05Cr 4.33Cr 45.23L 39.72L 36.94L 33.9L 63.7L 44Cr 64.68L 4.39Cr 1.71Cr 21Cr 1.7Cr 1.66Cr 74Cr
Net Debt -20Cr -2.12Cr -1.86Cr -1.73Cr -1.59Cr -2.98Cr -203.71Cr -3.02Cr -21Cr -8.02Cr -100.15Cr -7.94Cr -7.77Cr -346.27Cr -22Cr -2.31Cr -2.03Cr -1.89Cr -1.73Cr -3.25Cr -222.47Cr -3.3Cr -22Cr -8.75Cr -109.37Cr -8.67Cr -8.49Cr -378.16Cr
Logo Photocure ASA
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Employees
100
Date Price Change Volume
24/26/24 NOK 56.10 -0.53% 15,419
23/26/23 NOK 56.40 +0.18% 15,354
22/26/22 NOK 56.30 0.00% 48,088
21/26/21 NOK 56.30 -2.26% 84,627
20/26/20 NOK 57.60 -0.17% 12,401
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
56.10NOK
Average target price
84.00NOK
Spread / Average Target
+49.73%

Quarterly revenue - Rate of surprise